Menu Search
Equities

Endexx Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
EDXC:PKL

Endexx Corp

Actions
  • Price (USD)0.0003
  • Today's Change0.00 / 0.00%
  • Shares traded6.25k
  • 1 Year change-95.64%
  • Beta-0.8646
Data delayed at least 15 minutes, as of Feb 27 2026 16:26 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Endexx Corporation, through its operating divisions CBD Unlimited, Inc., and HYLA, develops and distributes all-natural, plant-based topical products, as well as non-nicotine vape products in the wellness and health market. CBD Unlimited Inc. is focused on developing, manufacturing, and distributing hemp-derived, cannabidiol-enhanced products. These products include full-spectrum oils, topicals, extracts, and pet products, all focused on supporting health and wellness. HYLA specializes in producing and selling organic, plant-based, zero-nicotine vape products. HYLA's product line includes a wide range of premium and mass-market vape devices that are manufactured in UL-certified facilities. HYLA is also exploring adding nicotine-based products to its portfolio. In Animal Sciences, it distributes its brand line PhytoBites for dogs and cats. The Company has global and domestic operations. The Company and its celebrity partner DJ Khaled launched a Men's Grooming Line named Blesswell.

  • Revenue in USD (TTM)4.64m
  • Net income in USD6.93m
  • Incorporated1997
  • Employees--
  • Location
    Endexx Corp38246 North Hazelwood CircleCAVE CREEK 85331United StatesUSA
  • Phone+1 (480) 595-6900
  • Fax+1 (480) 626-1696
  • Websitehttps://endexx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.